Jerome H Taylor1,2,3,4, Ewgeni Jakubovski1,5, Daniel Gabriel1,6, Michael H Bloch1,2. 1. 1 Child Study Center, Yale University , New Haven, Connecticut. 2. 2 Department of Psychiatry, Yale University , New Haven, Connecticut. 3. 3 Department of Psychiatry, University of Pennsylvania , Philadelphia, Pennsylvania. 4. 4 Department of Child and Adolescent Psychiatry and Behavioral Services, Children's Hospital of Philadelphia , Philadelphia, Pennsylvania. 5. 5 Department of Psychiatry, Social Psychiatry and Psychotherapy, Hannover Medical School , Hannover, Germany . 6. 6 Sewanee: The University of the South , Sewanee, Tennessee.
Abstract
BACKGROUND:Antipsychotic-related weight gain is a common clinically relevant side effect when treating psychotic disorders in pediatric populations, yet few predictors and no moderators of antipsychotic-related weight gain are known. METHODS: The Treatment of Early-Onset Schizophrenia Spectrum Disorders (TEOSS) study randomized 119 youths (age 8-19 years) with schizophrenia or schizoaffective disorder to 8 weeks of antipsychotic treatment withmolindone, risperidone, or olanzapine and assessed treatment response and side effects. In this secondary analysis, we used multivariable linear regression and receiver operating characteristic analysis to investigate predictors and moderators of weight change and percent weight change from baseline to week 8. RESULTS: Treatment assignment was the most discriminant predictor of weight change [F(2, 66) = 17.00, p < 0.001] and percent weight change [F(2, 66) = 16.85, p < 0.001]. Mean weight gain was 0.74 (standard deviation ±3.51) kg for molindone, 4.13 ± 3.79 kg for risperidone, and 7.29 ± 3.44 kg for olanzapine. After adjusting for treatment assignment, lower pretreatment hemoglobin A1C (HgbA1C) predicted more weight gain [F(1, 55) = 4.71, p = 0.03]. Diagnosis (schizoaffective vs. schizophrenia) moderated weight change [F(2, 63) = 6.02, p = 0.004] and percent weight change [F(2, 63) = 5.26, p = 0.008] such that schizoaffective diagnosis predicted larger weight gain for youths in the risperidone treatment arm. Age, sex, family income, baseline weight, and symptoms neither predicted nor moderated weight change or percent weight change. CONCLUSION: We identified prognostic subgroups and novel risk factors for antipsychotic-related weight gain. We confirmed that antipsychotic choice is extremely important for predicting future weight gain. We also found that younger age did not predict greater weight gain, in contrast to prior studies. Our findings require replication in an independent sample because we did not adjust for multiple comparisons to minimize false negatives. ClinicalTrials.gov Identifier: NCT00053703.
RCT Entities:
BACKGROUND: Antipsychotic-related weight gain is a common clinically relevant side effect when treating psychotic disorders in pediatric populations, yet few predictors and no moderators of antipsychotic-related weight gain are known. METHODS: The Treatment of Early-Onset Schizophrenia Spectrum Disorders (TEOSS) study randomized 119 youths (age 8-19 years) with schizophrenia or schizoaffective disorder to 8 weeks of antipsychotic treatment with molindone, risperidone, or olanzapine and assessed treatment response and side effects. In this secondary analysis, we used multivariable linear regression and receiver operating characteristic analysis to investigate predictors and moderators of weight change and percent weight change from baseline to week 8. RESULTS: Treatment assignment was the most discriminant predictor of weight change [F(2, 66) = 17.00, p < 0.001] and percent weight change [F(2, 66) = 16.85, p < 0.001]. Mean weight gain was 0.74 (standard deviation ±3.51) kg for molindone, 4.13 ± 3.79 kg for risperidone, and 7.29 ± 3.44 kg for olanzapine. After adjusting for treatment assignment, lower pretreatment hemoglobin A1C (HgbA1C) predicted more weight gain [F(1, 55) = 4.71, p = 0.03]. Diagnosis (schizoaffective vs. schizophrenia) moderated weight change [F(2, 63) = 6.02, p = 0.004] and percent weight change [F(2, 63) = 5.26, p = 0.008] such that schizoaffective diagnosis predicted larger weight gain for youths in the risperidone treatment arm. Age, sex, family income, baseline weight, and symptoms neither predicted nor moderated weight change or percent weight change. CONCLUSION: We identified prognostic subgroups and novel risk factors for antipsychotic-related weight gain. We confirmed that antipsychotic choice is extremely important for predicting future weight gain. We also found that younger age did not predict greater weight gain, in contrast to prior studies. Our findings require replication in an independent sample because we did not adjust for multiple comparisons to minimize false negatives. ClinicalTrials.gov Identifier: NCT00053703.
Entities:
Keywords:
antipsychotics; children; clinical trial; obesity; schizophrenia; side effects
Authors: Marc De Hert; Bie Peuskens; Ruud van Winkel; Dita Kalnicka; Linda Hanssens; Dominique Van Eyck; Sabien Wyckaert; Joseph Peuskens Journal: Schizophr Res Date: 2006-09-22 Impact factor: 4.939
Authors: David Fraguas; Christoph U Correll; Jessica Merchán-Naranjo; Marta Rapado-Castro; Mara Parellada; Carmen Moreno; Celso Arango Journal: Eur Neuropsychopharmacol Date: 2010-08-10 Impact factor: 4.600
Authors: Christoph U Correll; Peter Manu; Vladimir Olshanskiy; Barbara Napolitano; John M Kane; Anil K Malhotra Journal: JAMA Date: 2009-10-28 Impact factor: 56.272
Authors: H Oughli; E J Lenze; A E Locke; M D Yingling; Y Zhong; J P Miller; C F Reynolds; B H Mulsant; J W Newcomer; T R Peterson; D J Müller; G E Nicol Journal: J Psychiatr Res Date: 2019-04-23 Impact factor: 4.791
Authors: Jerome H Taylor; Nana Asabere; Monica E Calkins; Tyler M Moore; Sunny X Tang; Rose Mary Xavier; Alison K Merikangas; Daniel H Wolf; Laura Almasy; Ruben C Gur; Raquel E Gur Journal: Schizophr Res Date: 2019-12-26 Impact factor: 4.939
Authors: Robert C Smith; Lawrence Maayan; Renrong Wu; Mary Youssef; Zhihui Jing; Henry Sershen; Victoria Szabo; Jordan Meyers; Hua Jin; Jinping Zhao; John M Davis Journal: Psychopharmacology (Berl) Date: 2018-10-31 Impact factor: 4.530
Authors: Jerome H Taylor; Scott Appel; Matthew Eli; Aaron Alexander-Bloch; Lawrence Maayan; Raquel E Gur; Michael H Bloch Journal: J Child Adolesc Psychopharmacol Date: 2020-07-01 Impact factor: 2.576
Authors: Chi-Shin Wu; Alex R Luedtke; Ekaterina Sadikova; Hui-Ju Tsai; Shih-Cheng Liao; Chen-Chung Liu; Susan Shur-Fen Gau; Tyler J VanderWeele; Ronald C Kessler Journal: JAMA Netw Open Date: 2020-02-05